Pure Global
NCT06349343

CD19/BCMA HLA-independent TCR-T Cell Therapy for Refractory/Moderate-to-severe Systemic Lupus Erythematosus

Clinical Study of the Safety and Efficacy of CD19/BCMA HLA-independent TCR-T Cell Therapy for Refractory/Moderate-to-severe Systemic Lupus Erythematosus
Wuhan Union Hospital, China·Phase 1·ClinicalTrials.gov·biologicalNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Systemic Lupus Erythematosus
Drug/Device/Intervention
CD19/BCMA Hi-TCR-T cell therapy
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Wuhan Union Hospital, China
Timeline & enrollment
Phase
Phase 1
Start date
Apr 01, 2024
End date
Jan 01, 2026
Enrollment
20 participants
Primary outcome

Safety and tolerability

Summary

The purpose of the study is to explore the safety and efficacy of cluster of differentiation
 19 (CD19)/B cell maturation antigen (BCMA) human leukocyte antigen (HLA)-independent T cell
 receptor (TCR) -T therapy in refractory/moderate-to-severe systemic lupus erythematosus(SLE).

ICD-10 classifications
Systemic lupus erythematosusSystemic lupus erythematosus, unspecifiedLupus erythematosusSystemic lupus erythematosus with organ or system involvementOther forms of systemic lupus erythematosus
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06349343
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06349343 through Pure Global AI's free database. This Phase 1 trial is sponsored by Wuhan Union Hospital, China and is currently Not yet recruiting. The study focuses on Systemic Lupus Erythematosus. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.